

HIV antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study

Authors and Affiliations

- 1) Nava Yeganeh, Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA
- 2) Tara Kerin, Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA
- 3) Bonnie Ank, Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA
- 4) Heather Watts, Office of the Global AIDS Coordinator and Health Diplomacy, U.S. Dept. of State, Washington D.C.
- 5) Margaret Camarca, Westat, Rockville, MD
- 6) Esau C. Joao, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil
- 7) Jose Henrique Pilotto Hospital Geral de Nova Iguaçu, Nova Iguaçu and Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, (Fiocruz), Rio de Janeiro, Brazil
- 8) Valdilea Veloso, Laboratório de Pesquisa Clínica em DST e AIDS - Instituto de Pesquisa Clínica Evandro Chagas - Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil,
- 9) Yvonne Bryson, Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA
- 10) Glenda Gray, University of Witwatersrand/Chris Hani Baragwanath Hospital, Johannesburg, South Africa
- 11) Gerhard Theron, Department of Obstetrics and Gynecology, Stellenbosch University, CapeTown, South Africa

© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

- 12) Ruth Dickover, Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA
- 13) Mariza G. Morgado Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
- 14) Breno Santos, Hospital Conceicao, Porto Alegre, RS, Brazil;
- 15) Regis Kreitchmann, Hospital Femina, Porto Alegre, RS, Brazil
- 16) Lynne Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC
- 17) Karin Nielsen-Saines Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA

Correspondence/Address for Reprints: Nava Yeganeh MD, MPH, Dept of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States. Division of Infectious Disease-MDCC 22-442 10833 Le Conte Ave, Los Angeles, CA 90095. Telephone 310 825-5235. Fax 310-206-4764, email nyeganeh@mednet.ucla.edu

Summary: More than 10% of previously untreated HIV infected pregnant women and their infants had clinically significant antiretroviral drug resistant mutations. Drug related mutations did not appear to increase the risk of HIV transmission, but were transmitted to infants.

ABSTRACT:

Background: The presence of antiretroviral drug resistant mutations (DRMs) may be particularly problematic in HIV-infected pregnant women as it can lead to mother to child transmission (MTCT) of resistant HIV strains. This study evaluated the prevalence and the effect of antiretroviral DRMs in previously untreated mother-infant pairs.

Methods: A case-control design of 1:4 (1 transmitter to 4 non-transmitters) was utilized to evaluate DRMs as a predictor of HIV MTCT in specimens obtained from mother-infant pairs. ViroSeq HIV-1 Genotyping testing was performed on mother-infant specimens to assess for clinically relevant DRMs.

Results: One hundred and forty infants acquired HIV-infection; of these 123 mother-infant pairs (88%) had specimens successfully amplified using ViroSeq and assessed for drug resistance genotyping. Additionally, 483 (86%) of 560 women who did not transmit HIV to infants also had samples evaluated for DRMs. Sixty-three (10%) of 606 women had clinically relevant DRMs; 12 (2%) had DRMs against >1 drug class. Among 123 HIV-infected infants, 13 (11%) had clinically relevant DRMs, with 3 (2%) harboring DRMs against >1 drug class. In univariate and multivariate analyses, DRMs in mothers were not associated with increased HIV MTCT (AOR 0.8, 95% CI 0.4-1.5). Presence of DRMs in transmitting mothers was strongly associated with DRM presence in their infants ($p < 0.001$).

Conclusion: Pre-existing DRMs were common in untreated HIV infected pregnant women, but did not increase the risk of HIV MTCT. However, if women with DRMs are not virologically suppressed, they may transmit resistant mutations, thus complicating infant management.

Clinical Trials Registration Number: NCT00099359

Keywords:

Drug resistant mutations, mother to child transmission

INTRODUCTION:

Eliminating new HIV infections in infants born to HIV-infected mothers while improving maternal health continues to remain a high priority on the Joint United Nations Program on HIV/AIDS (UNAIDS) list of achievable goals.[1] HIV elimination depends largely on using combinations of antiretroviral (ARV) drugs to block HIV replication in HIV infected individuals, thus serving the dual purpose of improving the infected individuals' health while preventing transmission to others. [2, 3] However, HIV can develop ARV drug-associated resistance mutations (DRMs), which can decrease the efficacy of ARV treatment (ART). DRMs can be acquired following receipt of ARV drugs but can also be transmitted during primary infection in individuals without prior ARV exposure. In the case of pregnant women, ARV DRMs can be transmitted to the infant if the woman is not on effective ART that suppresses viral replication.[4] Antiretroviral resistance can thus impair the efficacy of future ART in mothers and in HIV-infected infants if the presence of DRMs is not promptly diagnosed and treatment is not appropriately adjusted.[5, 6] On the other hand, DRM are associated with fitness costs, possibly decreasing the likelihood of mother to child transmission.[7] The experience with single-dose nevirapine administered to mothers before birth and to infants at birth demonstrated the rapid development of DRMs in both mothers and infants because of the long half-life of nevirapine and because a single mutation can result in high level nevirapine drug resistance. [8] It has been demonstrated that resistant virus can be transmitted from mother to infant during pregnancy/labor or through breast milk. [9] DRMs can remain detectable for extended periods in an individual's viral population and indefinitely in viral reservoirs, rapidly re-emerging in the setting of re-exposure to the specific drug(s). [10] Viral evolution in the setting of DRMs can compromise the treatment of HIV-infected infants and post-partum women. [11, 12]

To evaluate the effect of maternal DRMs on HIV MTCT, we reviewed the prevalence of DRMs in a subset of treatment-naive mother-infant pairs enrolled in the NICHD /HPTN 040 (P1043)

perinatal clinical trial. [13] We also evaluated risk factors potentially associated with DRMs in both mothers and HIV-infected infants.

METHODS –

Study population: This was a secondary analysis evaluating the presence of DRMs in plasma specimens collected from participants who were enrolled and followed between April 2004 through January 2011 in the NICHD /HPTN 040 (P1043) study at sites in South Africa, Brazil and Argentina. Subjects in this study had not received ART during current pregnancy prior to labor because of late presentation to medical care and/or lack of prenatal care. Women were enrolled during labor or immediately after delivery. The aim of the parent study was to evaluate optimal infant antiretroviral prophylaxis to prevent intrapartum HIV transmission. Infants in group A received 6 weeks of ZDV alone, infants randomized to Group B received 6 weeks of ZDV plus 3 doses of nevirapine (NVP) during the first week of life and infants in Group C received 6 weeks of ZDV plus nelfinavir (NFV) and lamivudine (3TC) for the first two weeks of life. Infants enrolled in 040 were formula fed as breastfeeding was an exclusion criterion. [13]

For this analysis, our primary endpoint was whether DRMs resulted in an increase in HIV mother-to-child transmission (MTCT). We performed a case-control study of 140 mothers whose infants were HIV-infected, matching each case to 4 randomly selected controls, ultimately including 560 women whose infants were HIV-uninfected at six months of age (end of the study period). We also performed a second evaluation on blood specimens collected from all 140-HIV infected infants to evaluate the presence of DRMs in infants. All infants were followed for development of any serious adverse outcomes during the first 6 months of life. Infant HIV infection was diagnosed with two positive HIV DNA PCR results. Infants with positive DNA PCR within 48 hours of birth and confirmatory results on repeat testing were classified as having *in utero* HIV infection. Infants with a negative result at birth and positive results on

subsequent testing were classified as acquiring HIV infection through the *intrapartum* route. For mothers, blood specimens used for resistance testing was collected during their baseline study visit during labor prior to any study medications. The time point for infant ART resistance testing varied from birth to 6 months, however most specimens were obtained from study visits after infants had completed receiving study-related ARVs (e.g., after the six week ARV prophylaxis regimen was completed). The majority of infants were tested for the presence of DRMs at the 3-month visit (81%). The study was approved by local and collaborating institutional review boards.

Genotypic Drug Resistance: Viroseq testing (ViroSeq HIV-1 Genotyping System, Celera Diagnostics, Alameda, California) [14] was performed on all available mother-infant specimens to assess the presence of clinically relevant DRMs. Plasma was isolated from EDTA-anticoagulated whole blood within 6 hours of sample collection. Specimens with HIV-1 RNA levels (viral load) higher than 750,000 copies/ml were analyzed following 1:100 dilution. Plasma samples were stored frozen at -70 °C prior to genotypic analysis. Specimens were analyzed at three laboratories including the Fiocruz reference laboratory for the 040 study in Brazil, in the University of California Los Angeles, United States and Clinical Laboratory Services (CLS) Johannesburg, South Africa. All laboratories were Clinical Laboratory Improvement Amendments certified and certified by the National Institute of Allergy and Infectious Diseases (NIAID) for the performance of ViroSeq assay testing. HIV-1 genotyping was performed using the ViroSeq HIV-1 Genotyping System according to manufacturer's instructions, with the following exception: where limited volume was available, less than 0.5 ml of plasma was used for analysis. In this system, HIV-1 RNA is extracted from plasma samples, and one-fifth of the extracted RNA is reverse transcribed with murine Moloney virus RT. A 1.8-kb DNA fragment is

then amplified in the same tube in a single 40-cycle PCR with AmpliTaq gold polymerase and uracil N-deglycosylase decontamination control. PCR products are purified using spin columns and analyzed by agarose gel electrophoresis. The PCR products are sequenced with premixed BigDye sequencing reagents in seven separate reactions. BigDye terminator chemistry provides 98% accuracy at 550 bases for the ABI Prism 377 DNA Sequencer and 98.5% accuracy at 600 bases for the ABI Prism 310 Genetic Analyzer according to product bulletins issued by the manufacturer. The limit for ViroSeq testing was 1,000 copies/mL of viral load. Samples from subtypes B, F1, CF1 and C were properly amplified. There was mandatory amplification of the two positive controls; its sequencing with the seven primers generated an electropherogram with the two polymorphisms and one nucleotide insertion at the specific positions. No resistance mutations or mixed bases were accepted.

For analytical samples and controls, size of the sequenced fragments were around 600bp, and at least 6 out of 7 primer generating readable sequences which were overlapped to cover the total fragment. Once edited, the batch of analytical samples (generally 10-20/day were submitted to a website containing other laboratory sequences previously analyzed to check for contamination. The presence of hypermutation indicated in the Stanford University HIV Drug Resistance Database did not eliminate the sample from the study. The resulting sequences were assembled and analyzed using HIV-1 Genotyping System software. Clinical relevance was assigned by the investigator (Dr. Nielsen-Saines and Dr. Bryson) based on the Stanford University HIV Drug Resistance Database (<http://hivdb.stanford.edu/DR>).

Analysis: For the primary endpoint, univariate and multivariate logistic regression analyses were performed to evaluate whether HIV-1 log viral load, race, infant prophylaxis arm, country of origin, maternal CD4 count, maternal age and presence of maternal DRMs were associated with

an increased odds of MTCT. Our final model included the following predictors: HIV-1 log viral load, race, infant prophylaxis arm and maternal DRMs. We then performed another multivariate analysis evaluating whether DRMs against each drug in infant's neonatal prophylaxis resulted in increased MTCT. In this analysis, we calculated genotypic susceptibility scores against infant post-exposure prophylaxis regimens. A discrete value of 1 or 0 was given if the Stanford score was below 30 (susceptible) versus 30 or above (resistant) using the current Stanford University HIV Drug Resistance Database.

We then used univariate and multivariate logistic regression to evaluate the association between 5 types of maternal DRMs (non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI), multi-drug class mutation, and any mutation) with predictors including ethnicity, maternal age, maternal CD4+ T-cell counts, country of origin, log scale of maternal viral load category, infant HIV status, ZDV use during labor, and parity category.

For HIV infected infants with DRM, Fisher exact test was used to evaluate the association between each of 4 infant DRM types (NNRTI, NRTI, PI, and multi-drug class mutation) and presence of maternal DRMs. The p-values that were calculated in this analysis were all two-sided and statistical significance was set as $p < 0.05$. R version 3.3.3 statistical package was used to perform analyses.

RESULTS:

A total of 700 women had plasma specimens selected for resistance testing. Ninety four women (17 transmitters and 77 non-transmitters) with a mean viral load of 362 copies/ml (± 344.6) were excluded from the analysis because nucleic acid was unable to be amplified due to a low virus load. Similarly, 17 (12%) of 140 HIV infected infants did not have sufficient HIV nucleic acid to perform Viroseq testing because of a low viral burden. As shown in Figure 1, 63 (10.4%) of 606 HIV-infected women who had resistance testing performed had evidence of clinically relevant DRMs, with 12 women (2%) having DRMs against more than one class of ARV drugs. The DRMs observed included 25 (4%) mutations conferring resistance to PIs, 38 (6%) with mutations conferring resistance to NNRTIs, and 12 (2%) mutations conferring resistance to NRTIs.

In the 123 HIV-infected infants, clinically relevant DRM were found in 13 infants (11%) with 3 infants (2%) having DRM against more than 1 class of ARV drugs. Two infants (2%) had mutations conferring resistance to PIs, 12 (10%) had mutations conferring resistance to NNRTIs and 2 (2%) had mutations conferring resistance to NRTI medications.

As seen in Table 1, mothers enrolled in this analysis were relatively young (mean age 26.7 years), majority non-white, with 45.5% self-identified as black and 31.5% self-identified as mixed, and mostly recruited in South America (78.9%). Only 12.7% had CD4+ T-cell count less than 200 cells/uL and most (65.7%) had HIV-1 viral loads >10,000 copies/mL at the time of labor and delivery when the study enrolled subjects. Among the 606 mothers selected for this analysis, 131 (21.7%) transmitted HIV to their infants, with 87/131 (66%) transmissions occurring in-utero and 44/131 (34%) intrapartum. Consistent with the study results

demonstrating superiority of 2- and 3-drug infant prophylaxis to ZDV alone, infected infants were most commonly in the ZDV prophylaxis arm (N=59, 44.7%), followed by 36 (27.6%) each in the double ART arm (ZDV + NVP) and triple ART arm (ZDV + NFV + 3TC). Of the 123 HIV-infected infants included in the DRM analysis, 81 (65.9%) were determined to be infected in-utero, and 42 (34.1%) were infected during the intrapartum period.

In the univariate and multi-variate analyses, the presence of DRMs in mothers was not associated with increased risk of HIV MTCT (AOR 0.8, 95% CI 0.4-1.5). High log viral load and infant prophylaxis with ZDV alone were the only predictors of HIV MTCT (log viral load OR 1.4, 95% CI 1.2-1.6, infant prophylaxis with ZDV vs ZDV+NVP OR 1.6, 95% CI 1.03-2.6). A separate analysis was performed where only maternal DRMs that had a genotypic susceptibility score of less than 1 to drugs given for the infant prophylaxis regimen were included. In this more directed analysis with a lower sample size, we still found that DRM did not affect odds of mother to child transmission (AOR 0.83, 95% CI 0.3-1.9), although the confidence interval was increased. As seen in Table 2, our univariate analysis suggests that age, T cell CD4 count, log maternal viral load and parity did not appear to predict the presence of DRMs in mothers. However, as compared to living in the Americas, being from South Africa was protective against having any DRMs in our analysis (OR 0.4, 95% CI 0.2-0.9) as well as for DRMs associated with PI resistance (OR 0.2, 95% CI 0.01-0.7). Furthermore, being of mixed ethnicity was found to be associated with having NRTI DRM as compared to being black, but with a large confidence interval (OR 11.9, 95% CI 2.2-222).

As seen in Figure 2, there was a diversity of mutations detected in mothers enrolled into the trial with 59 mutations against NNRTIs, 55 mutations against NRTIs, and 106 mutations against PIs. Mutations with asterisks were included in the analyses as they were considered clinically relevant by the investigators designing the study. In mothers, the most common clinically relevant mutation was the NNRTI mutation K103N, found in 15 participants.

Table 3 details information about the 13 HIV-infected infants with DRMs. Presence of any DRMs in mother was strongly associated with presence of any DRMs in infants ($p < 0.001$). All infants had at least one of the mothers' DRM mutations, except in 3 cases (Infants 9, 12, 13) where infants developed resistance to NNRTIs even though there was no evidence of any NNRTI DRMs in the mother, and in one case (Infant 2) where the infant developed a different NNRTI mutation than the mother (Y181C in infant vs K103N in mother). All 4 of these infants were infected in utero, and 3 of them were in the ZDV + NVP prophylaxis arm. None of the infants with resistant mutations succumbed during the study period; significant health events are listed in Table 3.

DISCUSSION:

Our study's results reveal that DRMs can commonly affect HIV infected individuals despite the lack of prior ARV exposure, with DRMs affecting more than 10% of treatment naive pregnant women and their infants. In Brazil, a 10.4% rate of DRMs in pregnancy found in this study agrees with most other studies evaluating ARV drug resistance in pregnant women, with rates ranging from 9-13%,[15-17]. More recent reports are showing a trend towards higher rates of DRMs in pregnant women in Rio de Janeiro, with a prevalence rate of 17.2% in treatment-naïve

patients.[18] In other cities of Brazil, such as Belo Horizonte, a DRM rate of 9.8% in infants is consistent with published reports.[19] In contrast, since our study's completion, reported rates of DRMs are much higher in South Africa with studies demonstrating that more than 50% of HIV-infected infants are infected with NNRTI resistant strains, and emphasizing the need for PI therapy for perinatally infected infants.[20, 21]. Therefore, our findings support the growing literature highlighting the importance of performing resistance testing on newly diagnosed and/or treatment naïve individuals with HIV prior to initiating ARTs, especially if they are pregnant, to optimize all MTCT strategies to avoid transmission of resistant HIV strains to the infant.

It has been hypothesized that infant post-exposure ARV prophylaxis may be less effective in the presence of drug-resistant maternal virus exposure, increasing the potential for intrapartum HIV MTCT. In our analysis, consistent with another published study looking at DRMs in pregnant women in Brazil, maternal ARV DRM did not appear to increase the risk of HIV MTCT. [17] Viral load and infant post exposure prophylaxis remain the most significant predictors of HIV transmission. Living in an area with high levels of ARV use seems to be the strongest predictor of having and transmitting ARV DRMs. We surmise that the association between living in South America and higher risk of maternal DRMs, especially against PI medications, is secondary to more widely available ART use in Brazil, where most of the study recruitment occurred, as compared to South Africa during the study period. In Brazil, by the end of 2006, 100% of all registered AIDS cases in Brazil were receiving combination ART, including protease inhibitors.[22, 23] whereas in South Africa, it is estimated that only 5.1% of ART-eligible individuals were on ART in 2004, rising to 79% by the end of 2011, with less frequent PI use. [24][25, 26]

The most frequent ARV DRMs identified in both mothers and infants likely reflected the first-line NNRTI ART therapy recommended in both countries.[28] Brazil had notably higher frequency of NRTI mutations, probably secondary to the use of ZDV prophylaxis during pregnancy for PMTCT prior to implementation of widespread use combination ART.[29] Infant DRMs largely mirrored those of their mothers, except in 3 cases where infants were infected in utero. These 3 infants developed resistance to NNRTIs following exposure to a prophylaxis regimen that included 3 doses of nevirapine, which is well known to result in resistance after minimal exposure, due to this drug's low genetic barrier to resistance. [20] [30] We hypothesize that these 3 infants acquired this DRM because their infant prophylaxis included nevirapine.

Studies have demonstrated that as the virus replicates and resistance mutations arise to circumvent selective ART pressure, viral fitness may be sacrificed, rendering the virus less likely to be efficiently transmitted. [31] [7] [32] [33] It is important to note that in high-risk situations such as detectable maternal viremia throughout pregnancy, caution should be exercised when providing ARV prophylaxis with drugs that have a low genetic barrier to development of DRM as this may compromise future HIV treatment management of these children. The benefit of reduced intrapartum transmission with combination prophylaxis must be balanced against the risk of DRM development if in utero transmission has already occurred.

The present study has some limitations. Although most patients were ART-naïve having been first diagnosed at delivery, the exact number of ARV-experienced women enrolling in the study is not available, as that information was not collected. However, parity was evaluated as a

potential predictor for presence of DRMs and a higher rate of DRMs in women with prior pregnancies was not detected. Another limitation is that the number of cases where infants harbored resistance mutations was small, and so the analyses might not have had enough power to detect possible predictors of DRMs in infants.

Our results strongly support the recommendation that all pregnant women and HIV-infected infants undergo HIV genotypic resistance testing prior to initiation of ART, especially if nevirapine was used for post-exposure prophylaxis regimens for the neonate. Infants at high risk of HIV acquisition should receive combination ARV regimens for prophylaxis, with attention given to early diagnosis and prompt initiation of ARV treatment in case of infection, in order to circumvent further development of DRMs and compromise of HIV ART management.

NOTES:**Authorship:**

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all aspects of manuscript development.

Acknowledgement:

We thank the patients and their families who enrolled in this trial; and Marita McDonough and Lauren Petrella from Boehringer Ingelheim Pharmaceuticals and Helen Watson from GlaxoSmithKline (on behalf of ViiV Healthcare) for assistance with the donation of study drugs from their respective companies for the conduct of the study.

Disclaimer:

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institutes of Health or the U.S. Department of Health and Human Services or the U.S. Department of State.

Funding Source:

This work was supported by the National Institute of Health [K23 AI118584-02]. The HPTN 040 study was supported by National Institute of Health Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986 (Brazilian AIDS Prevention Trials International Network), NIAID/ NIH. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious

Diseases (NIAID) [U01 AI068632], the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH) [AI068632]. In addition, the study was supported in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), and GlaxoSmithKline on behalf of ViiV Healthcare. Boehringer-Ingelheim Pharmaceuticals, Inc and GlaxoSmithKline were given the opportunity to check the data used in the present manuscript for factual accuracy only. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH).

Conflict of Interest:

None of the authors have a potential conflict of interest or funding source to disclose.

References:

1. Joint United Nations Programme on HIV/AIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mother's alive. Available at: http://www.unaids.org/en/resources/documents/2015/JC2774_2015ProgressReport_GlobalPlan. Accessed Feb 13.
2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *The New England journal of medicine* **2011**; 365(6): 493-505.
3. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. *The Cochrane database of systematic reviews* **2011**; (7): CD003510.
4. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. *International journal of epidemiology* **2007**; 36(5): 1009-21.
5. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. *The New England journal of medicine* **2007**; 356(2): 135-47.
6. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *The New England journal of medicine* **2010**; 363(16): 1510-20.
7. Yang WL, Kouyos RD, Boni J, et al. Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. *PLoS Pathog* **2015**; 11(3): e1004722.
8. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. *The Journal of infectious diseases* **2007**; 195(5): 711-5.
9. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. *The Journal of antimicrobial chemotherapy* **2009**; 63(1): 170-7.

10. Wind-Rotolo M, Durand C, Cranmer L, et al. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. *The Journal of infectious diseases* **2009**; 199(9): 1301-9.
11. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **2009**; 48(4): 462-72.
12. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. *Proceedings of the National Academy of Sciences of the United States of America* **2011**; 108(22): 9202-7.
13. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *The New England journal of medicine* **2012**; 366(25): 2368-79.
14. Eshleman SH, Hackett J, Jr., Swanson P, et al. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. *J Clin Microbiol* **2004**; 42(6): 2711-7.
15. Lima YA, Reis MN, Cardoso LP, Stefani MM. HIV-1 infection and pregnancy in young women in Brazil: socioeconomic and drug resistance profiles in a cross-sectional study. *BMJ open* **2016**; 6(7): e010837.
16. Pilotto JH, Grinsztejn B, Veloso VG, et al. Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive HIV-infected pregnant women in Rio de Janeiro, Brazil. *AIDS research and human retroviruses* **2013**; 29(4): 681-6.
17. de Lourdes Teixeira M, Nafea S, Yeganeh N, et al. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil. *International journal of STD & AIDS* **2015**; 26(13): 922-8.
18. Delatorre E, Silva-de-Jesus C, Couto-Fernandez JC, Pilotto JH, Morgado MG. High HIV-1 Diversity and Prevalence of Transmitted Drug Resistance Among

- Antiretroviral-Naive HIV-Infected Pregnant Women from Rio de Janeiro, Brazil. *AIDS research and human retroviruses* **2017**; 33(1): 68-73.
19. Ferreira FG, Pinto JA, Kakehasi FM, et al. Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically Infected children in Belo Horizonte, Brazil. *AIDS research and human retroviruses* **2010**; 26(2): 229-32.
 20. Kanthula R, Rossouw T, Feucht UD, et al. Persistence of HIV-drug-resistance among South African Children given Nevirapine to Prevent Mother-to-Child-Transmission. *Aids* **2017**.
 21. Kuhn L, Hunt G, Technau KG, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. *Aids* **2014**; 28(11): 1673-8.
 22. Dispõe sobre a distribuição gratuita de medicamentos aos portadores de HIV e doentes de Aids. Lei nº 9313. Brasília, **1996**.
 23. Oliveira-Cruz V, Kowalski J, McPake B. Viewpoint: the Brazilian HIV/AIDS 'success story'--can others do it? *Tropical medicine & international health : TM & IH* **2004**; 9(2): 292-7.
 24. Adam MA, Johnson LF. Estimation of adult antiretroviral treatment coverage in South Africa. *S Afr Med J* **2009**; 99(9): 661-7.
 25. Johnson LF. Access to Antiretroviral Treatment in South Africa, 2004-2011. *Southern African Journal of HIV Medicine* **2012**; 13(1).
 26. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. *PLoS medicine* **2012**; 9(7): e1001245.
 27. Dilernia DA, Lourtau L, Gomez AM, et al. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. *Aids* **2007**; 21(10): 1355-60.
 28. National Department of Health South Africa 2004. National Antiretroviral Treatment Guidelines. Available at: http://www.hst.org.za/uploads/files/sa_ART_Guidelines1.pdf. Accessed March 30.

29. Greco DB, Simao M. Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives. *Aids* **2007**; 21 Suppl 4: S37-45.
30. Persaud D, Bedri A, Ziemniak C, et al. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. *AIDS research and human retroviruses* **2011**; 27(8): 823-9.
31. Wang Z, Zhang J, Li F, et al. Drug resistance-related mutations T369V/I in the connection subdomain of HIV-1 reverse transcriptase severely impair viral fitness. *Virus Res* **2017**; 233: 8-16.
32. Lloyd SB, Lichtfuss M, Amarasena TH, et al. High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. *Virology* **2016**; 492: 1-10.
33. Weber J, Rose JD, Vazquez AC, et al. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors. *PLoS One* **2013**; 8(6): e65631.

Additional members of the NICHD/HPTN 040/PACTG 1043 protocol team: Argentina, Buenos Aires- Foundation for Maternal and Infant Health (FUNDASAMIN): Edgardo Szyld, Silvia Marzo. Brazil, Belo Horizonte- Federal University of Minas Gerais: Flavia Faleiro Ferreira, Fabiana Kakehasi. Porto Alegre-Hospital Nossa Senhora da Conceicao: Rita Lira. Porto Alegre-Hospital Femina: Carla Franceschini de Fraga Rita Lira. Porto Alegre-Irmandade da Santa Casa de Misericordia de Porto Alegre: Debora Fernandes Coelho, Alberto Sanseverino, Luis Carlos Ribeiro. Rio de Janeiro-Hospital dos Servidores do Estado: M. Leticia Santos Cruz, Ezequias Martins, Jacqueline Anita de Menezes, Luisa Andrea Torres Salgado. Rio de Janeiro- Hospital Geral de Nova Iguaçu: Ana Valeria Cordovil, Andréa Gouveia, Priscila Mazzucanti, Jorge Eurico Ribeiro. Rio de Janeiro- Laboratório de AIDS e Imunologia Molecular- Instituto Oswaldo Cruz- Fundação Oswaldo Cruz: Marisa G. Morgado. Sao Paulo-Universidade de Sao Paulo: Geraldo Duarte, Adriana Aparecida Tiraboschi Barbaro, Carolina Sales Vieira. Sao Paulo- Universidade Federal de Sao Paulo: Regina Succi. South Africa, Cape Town-Stellenbosch University and Tygerberg Hospital: Mark Cotton, Jeanne Louw, Elke Maritz. Johannesburg-Perinatal HIV Research Unit, University of Witwatersrand and Chris Hani Baragwanath Hospital: Sarita Lalsab, Shini Legoete, James Alasdair McIntyre, Mandisa Nyati. United States, Baltimore-Johns Hopkins University: Allison Agwu, Jean Anderson, Joan Bess, Jonathan Ellen, Todd Noletto, Nancy Hutton. Boston- Boston University School of Medicine: Mark Mirochnick. Gainesville-Shands Hospital: Carol Delany, Robert M. Lawrence. Jacksonville-University of Florida: Chas Griggs, Mobeen Rathore, Kathleen Thoma,Michelle Tucker. Long Beach- Miller Childrens Hospital: Audra Deveikis, Susan Marks. Newark-University Medical and Dental School of NJ: Linda Bettica, James M. Oleske. San Juan City-San Juan City Hospital: Midnela Acevedo Flores, Elvia Pérez. Davis- University of California at Davis: Ruth Dickover. Los Angeles- University of California Los Angeles: Bonnie Ank, Oswaldo Cruz Foundation, Rio de Janeiro

(FIOCRUZ): Francisco Inacio Bastos, Ronaldo Iserio Moreira, Marilia Santini de Oliveira, Monica Derrico, Valéria Ribeiro, Thiago Torres e FIOTEC (Fundação para o Desenvolvimento Científico e Tecnológico). Westat, Inc.: Emmanuel Aluko, James Bethel, Yolanda Bertucci, Jennifer Bryant, Patty Chen, Barbara Driver, Ruby Duston, Adriana Ferreira, Priya Guyadeen, Sarah Howell, Marsha Johnson, Linda Kaufman, Naomi Leshabane, Lilya Meyerson, Rita Patel, Lubima Petrova, Georgine Price, Susan Raitt, Scott Watson, Yiling Xu, Eunice Yu. Other protocol team members included George Siberry, Jack Moye, and Jennifer Read from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Elizabeth Smith and Sheryl Zwierski from the National Institute of Allergy and Infectious Diseases (NIAID).

Figure legends:

Figure 1: Flow chart of HIV infected mothers (a) and infants (b) included in this study.

DRM: Drug resistant mutation, PI: Protease inhibitor, NRTI: nucleoside reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor

*12 mothers and 3 infants with DRM against more than one class of antiviral

Figure 2: Graphs showing percentage of mutations found in samples collected from HIV infected mothers (Blue, total n=606) and in infants (Red, total n=123). Asterisk (*) marks mutations included in our analysis as clinically relevant mutations, and plus signs (+) refer to mutations that in conjunction with another mutation were clinically relevant. These were assigned by study investigators based on the Stanford University HIV Drug Resistance Database (<http://hivdb.stanford.edu/DR>) at the time the study was conducted. NNRTI (non-nucleoside reverse transcriptase inhibitors), NRTI (nucleoside reverse transcriptase inhibitors), PI (protease inhibitor)

Table 1: Demographics and characteristics of HIV infected mothers and infants

	n	%
MOTHERS (N: 606)		
Age		
13-24 years	241	39.8%
25-29 years	167	27.6%
30 years and over	198	32.7%
Ethnicity		
Black	276	45.5%
Mixed	191	31.5%
White	139	22.9%
Region		
Americas	478	78.9%
South Africa	128	21.1%
Viral Load (copies/mL)		
<=10,000	208	34.3%
10,001-100,000	304	50.2%
>100,000	94	15.5%
CD 4 count (cells/mm³)		
<200	77	12.7%
200 to 500	283	46.7%
>500	239	39.4%
Missing	7	1.2%
Infant status		
In Utero	87	14.4%
Intrapartum	44	7.3%
Uninfected	475	78.4%
Parity		
One	114	18.8%
More than 1	491	81.0%
INFANTS (N=123)		
Age testing performed		
Less than 3 months	23	18.7%
3 months or later	100	81.3%
Infant prophylaxis medications		
Zidovudine only	55	44.7%
Zidovudine and nevirapine	34	27.6%
Zidovudine, nelfinavir & lamivudine	34	27.6%

Infant HIV transmission route		
In Utero	81	65.9%
Intrapartum	42	34.1%
Intrapartum zidovudine exposure	58	47.2%

Table 2: Possible predictors for drug associated resistant mutations in 606 HIV infected pregnant women

	Resistance to >1 class of drugs (Yes)	Presence of NNRTI Resistant mutation (Yes)	Presence of NRTI Resistant mutation (Yes)	Presence of PI Resistant mutation (Yes)	Presence of any drug- associated resistant mutation	No clinically relevant mutations	OR ^a (95%CI)
Total n (%)	9 (1.5)	38 (6.3)	12 (2.0)	25 (4.1)	63 (10.4)	543(89.6)	
Age mean \pmSD	30.3 \pm 6.9	26.7 \pm 6.4	25.8 \pm 5.4	25.2 \pm 6.7	35.5 \pm 6.1	26.8 \pm 6.2	0.97 (0.9-1)
Ethnicity n (% n/N)							
Black (N=276)	2 (0.7)	16 (5.8)	1 (0.4)	7 (2.5)	22 (8)	254 (92)	Reference
Mixed (N=191)	6 (3.1)	13 (6.8)	8 (4.2) ^b	11 (5.8)	23 (12)	168 (88)	1.6 (0.9-2.9)
White (N=139)	1 (0.7)	9 (6.5)	3 (2.2)	7 (5)	18 (13)	121 (87)	1.7 (0.9-3.3)
Region n (% n/N)							
Americas (N=478)	9 (1.9)	32 (6.7)	12 (2.5)	24 (5.0)	56 (11.7)	422 (88.3)	Reference
South Africa (N=128)	0	6 (4.7)	0	1 (0.8) ^c	7 (5.5)	121 (94.5)	0.4 (0.2-0.9)*
Log Viral Load mean cells/ml (SD)	10.8 \pm 1.6	9.8 \pm 1.8	10.6 \pm 1.7	10.1 \pm 1.4	9.8 \pm 1.6	9.9 \pm 1.6	0.95 (0.8-1.1)
CD 4 count mean cells/mm³ (SD)	456.2 \pm 278	463.7 \pm 210	472.5 \pm 308	553.4 \pm 295	497.6 \pm 248	481.2 \pm 283	1
Infant status n (% n/N)							
In Utero (N=87)	2 (2.3)	6 (6.9)	2 (2.3)	2 (2.3)	7 (8)	80 (92)	0.7 (0.3-1.5)
Intrapartum (N=44)	1 (2.3)	3 (6.8)	0	2 (4.5)	4 (9.1)	40 (91)	0.8 (0.2-2.1)
Uninfected (N=475)	6 (1.3)	29 (6.1)	10 (2.1)	21 (4.4)	52 (10.9)	423 (89)	Reference
Parity n (% n/N)							

1 (N=114)	3 (2.6)	9 (7.9)	3 (2.6)	8 (7)	15 (13.2)	99 (87)	Reference
≥ 2 (N=491)	5 (1)	28 (5.7)	8 (1.6)	16 (3.3)	47 (9.6)	444 (90.4)	0.7 (0.4-1.3)

^aOdds ratio evaluating predictors of having any drug-associated resistant mutations versus not having clinically relevant mutations.

^bBeing of mixed ethnicity was found to be associated with having a mutation conferring resistance to NRTI as compared to being black (p 0.01, OR 11.9 (2.2-222)).

^cBeing of South African descent was protective for acquiring a mutation against PI as compared to being from Americas (p 0.04, OR 0.2, 95 %CI 0.01-0.7)

*P<0.05

NRTI: Nucleoside reverse transcriptase inhibitor, NNRTI: Non-nucleoside transcriptase inhibitor, PI: Protease inhibitor.

	Maternal DRM	Infant DRM	Age when DRM detected	Drugs affected by DRM	Neonatal arm for ppx	HIV transmission type	Adverse infant outcome up to 6 months
Infant 1	D67N, T215Y, K103N, D30N, N88D	D67N, T215Y, K103N, D30N, N88D	3 MO	NRTI, PI, NNRTI	C	IN UTERO	ABNORMAL LIVER FUNCTION TESTS (INCREASING AST), POSSIBLE CONGENITAL SYPHILIS (MOTHER WITH POSITIVE VDRL, NOT ADEQUATELY TREATED), THROMBOCYTOPENIA
Infant 2	K103N	Y181C	6 MO	NNRTI	C	IN UTERO	
Infant 3	K103N	K103N, V108I	3 MO	NNRTI	B	IN UTERO	SEPSIS EAR INFECTIONS
Infant 4	V179E	V179E	3 MO	NNRTI	A	INTRAPARTUM	
Infant 5	A98G	A98G	4-6 WK	NNRTI	B	IN UTERO	
Infant 6	K103N	K103N	3 MO	NNRTI	B	INTRAPARTUM	
Infant 7	V179E, L10F	V179E	3 MO	NNRTI	C	INTRAPARTUM	
Infant 8	V179D	V179D	3 MO	NNRTI	A	IN UTERO	NEUTROPENIA
Infant 9	None	K103N	3 MO	NNRTI	B	IN UTERO	NEUTROPENIA
Infant 10	D67G, L210W, T215S, K219E, D30N, N88D	D67G, L210W, T215S, K219E, D30N, N88D	3 MO	NRTI, PI	C	IN UTERO	PNEUMONIA
Infant 11	E138K	E138K	3 MO	NNRTI	A	IN UTERO	
Infant 12	None	V118I, K103N, V106A, V106M	4-6 WK	NNRTI	B	IN UTERO	
Infant 13	None	Y181C	3 MO	NNRTI	B	IN UTERO	

DRM: Drug associated resistant mutation, NRTI: Nucleoside reverse transcriptase inhibitor, NNRTI: Non-nucleoside transcriptase inhibitor, PI: Protease inhibitor.

Infant post-exposure prophylaxis study arm: Group A--6 weeks of zidovudine alone, Group B--6 weeks of zidovudine plus 3 doses of nevirapine during the first 8 days of life (2-drug group), Group C; 6 weeks of zidovudine plus 2 weeks of nelfinavir and lamivudine (3-drug group).

Figure 1.




Figure 2.




Figure 2: Graph showing percent of mutations found in samples collected from HIV infected mothers (Blue, n=606) and in infants (Red, n=123). Asterik (*) marks mutations considered clinically relevant in our analysis, and plus signs (+) refer to mutations that in conjunction with another mutation were clinically relevant. These were assigned by study investigators based on the Stanford University HIV Drug Resistance Database (<http://hivdb.stanford.edu/DR>) at the time the study was conducted. NNRTI (non-nucleoside reverse transcriptase inhibitors), NRTI (nucleoside reverse transcriptase inhibitors), PI (protease inhibitor)